All data are based on the daily closing price as of June 6, 2025
l

Lunit

328130.KQ
35.60 USD
0.19
+0.54%

Overview

Last close
35.60 usd
Market cap
1.03B usd
52 week high
64.83 usd
52 week low
23.39 usd
Target price
36.07 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
20.4781
Price/Book Value
8.1495
Enterprise Value
1.05B usd
EV/Revenue
20.8301
EV/EBITDA
-45.3273

Key financials

Revenue TTM
50.24M usd
Gross Profit TTM
50.24M usd
EBITDA TTM
-48.96M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
280.95M usd
Net debt
9.53M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
  • Symbol
    328130.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Health Information Services
  • CEO
    Mr. Beomseok Brandon Suh
  • Headquarter
    Seoul
  • Web site
    https://www.lunit.io
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top